These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39178204)

  • 1. Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.
    Tan YJ; Linden S; Ong SC
    PLoS One; 2024; 19(8):e0305257. PubMed ID: 39178204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
    Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
    Davis JA; Booth D; McEwan P; Solomon SD; McMurray JJV; de Boer RA; Comin-Colet J; Bachus E; Chen J
    Eur J Heart Fail; 2024 Mar; 26(3):664-673. PubMed ID: 38509642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
    Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
    ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
    Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
    JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
    Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
    Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
    Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
    Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials.
    García-Moll X; Croci F; Solé A; Hartgers-Gubbels ES; Calleja-Hernández MA
    Expert Rev Cardiovasc Ther; 2024; 22(1-3):131-139. PubMed ID: 38416135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
    Tang Y; Sang H
    Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
    Ong SC; Low JZ; Linden S
    Front Pharmacol; 2023; 14():1195124. PubMed ID: 37342587
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam - findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model.
    Varghese L; Chang PW; Juntarasiripas S; Pham H; Uster A
    J Med Econ; 2024; 27(1):836-848. PubMed ID: 38916150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
    Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
    Kolovos S; Bellanca L; Groyer H; Rosano GMC; Solé A; Gaultney J; Linden S
    ESC Heart Fail; 2023 Dec; 10(6):3385-3397. PubMed ID: 37670496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England.
    Kolovos S; Bellanca L; Groyer H; Rosano G; Gaultney J; Linden S
    J Cardiovasc Med (Hagerstown); 2023 Oct; 24(10):758-764. PubMed ID: 37577867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom.
    Ramos M; Gerlier L; Uster A; Muttram L; Frankel AH; Lamotte M
    J Med Econ; 2024; 27(1):777-785. PubMed ID: 38758099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
    Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Reifsnider OS; Rakonczai P; Stargardter M; Murata T; Hirase T; Nitta D
    J Cardiol; 2023 Jun; 81(6):522-530. PubMed ID: 36858174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.